The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults
Primary Purpose
Depression
Status
Completed
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
Sertraline
Sponsored by

About this trial
This is an interventional treatment trial for Depression
Eligibility Criteria
Depressed group
Inclusion Criteria:
- Clinical diagnosis of Major Depression
- English-speaking
- If currently on an antidepressant, willing to undergo a 2 week washout.
Exclusion Criteria:
- Lifetime bipolar disorder
- Current psychotic disorder or substance use disorder
- Dementia
- Poor baseline mobility or baseline severe gait disorder
- On treatment with fluoxetine or mood stabilizer
- Severe renal impairment, bleeding disorder, recent gastric bleeding or hemorrhagic stroke in past 3 months
- Poor response or serious adverse event with sertraline in the past.
Comparison group
Inclusion Criteria:
- English-speaking
Exclusion Criteria:
- Lifetime diagnosis of depression or dementia
- Currently on antidepressant medication or mood stabilizer
- Poor baseline mobility or baseline severe gait disorder
Sites / Locations
- Toronto Rehabilitation Institute, University Health Network
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Depression
Comparison group (non-depressed)
Arm Description
Sertraline 50- 200mg
No intervention
Outcomes
Primary Outcome Measures
Change in number of steps to recover balance compared to baseline
Number of steps
Secondary Outcome Measures
Change in CTX-I (Serum collagen type-I cross-linked C-telopeptide)
pg/ml
Change in P1NP (Serum procollagen type-1 N-terminal polypeptide)
ng/ml
Change in stride variability from baseline
ms
Change in centre of pressure sway velocity under dual task conditions
cm/s
Full Information
NCT ID
NCT02228005
First Posted
July 23, 2014
Last Updated
May 3, 2017
Sponsor
University Health Network, Toronto
1. Study Identification
Unique Protocol Identification Number
NCT02228005
Brief Title
The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults
Official Title
The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
July 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Health Network, Toronto
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to examine the effects of sertraline treatment of depression in older adults on gait stability, balance recovery reactions, and markers of bone metabolism. This is a pilot study that will determine feasibility and generate hypotheses for a larger definitive study.
Detailed Description
Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant medication frequently used to treat depressive and anxiety disorders in the elderly. Although widely considered to be a safe option, several observational studies have found that SSRIs have as strong an association with falls as other psychotropic medications including tricyclic antidepressants and benzodiazepines. However, the potential mechanism for a link between SSRIs and falls is unclear. Compared to other psychotropic medications, SSRIs have lower rates of side effects that could contribute to falls, including sedation, orthostatic blood pressure changes, and anticholinergicity. Interestingly, SSRIs have also been associated with fractures, more so than other classes of antidepressants, in both administrative database studies and prospective cohort studies that control for falls history. Serotonin is known to play a role in regulating bone mass and some studies have found a loss of bone mass in individuals on SSRI treatment.
The association of SSRIs with falls and fractures is confounded by depression which is itself associated with falls, gait instability, bone loss and fractures. The goal of this study is to disentangle the contribution of the disease versus the treatment to risk of falls and fractures. As a first step towards this goal, this pilot study will: i) estimate effect sizes for statistical power calculations for an adequately powered study; and ii) examine the feasibility of timely recruitment of older patients with major depression who have not taken antidepressant medication for a minimum of 2 weeks prior to entering the study.
To address our research question, we have designed a prospective observational pilot study. Older adults with depression will be assessed at baseline, and then 3,6, and 12 weeks after initiation of sertraline antidepressant therapy. A non-depressed comparison group will be used to control for the learning effects of repeated assessment. The outcomes of interest are changes in gait, static balance, and dynamic balance recovery reactions. Our primary outcomes are the short-term changes in these variables at 3 weeks, but we will also perform a longitudinal analysis to assess change over 12 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Depression
Arm Type
Experimental
Arm Description
Sertraline 50- 200mg
Arm Title
Comparison group (non-depressed)
Arm Type
No Intervention
Arm Description
No intervention
Intervention Type
Drug
Intervention Name(s)
Sertraline
Other Intervention Name(s)
Zoloft
Intervention Description
Protocolized titration from 50 to max 200mg based on response and tolerance.
Primary Outcome Measure Information:
Title
Change in number of steps to recover balance compared to baseline
Description
Number of steps
Time Frame
Baseline, 3 weeks
Secondary Outcome Measure Information:
Title
Change in CTX-I (Serum collagen type-I cross-linked C-telopeptide)
Description
pg/ml
Time Frame
12 weeks
Title
Change in P1NP (Serum procollagen type-1 N-terminal polypeptide)
Description
ng/ml
Time Frame
12 weeks
Title
Change in stride variability from baseline
Description
ms
Time Frame
Baseline, 3 weeks
Title
Change in centre of pressure sway velocity under dual task conditions
Description
cm/s
Time Frame
Baseline, 3 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Depressed group
Inclusion Criteria:
Clinical diagnosis of Major Depression
English-speaking
If currently on an antidepressant, willing to undergo a 2 week washout.
Exclusion Criteria:
Lifetime bipolar disorder
Current psychotic disorder or substance use disorder
Dementia
Poor baseline mobility or baseline severe gait disorder
On treatment with fluoxetine or mood stabilizer
Severe renal impairment, bleeding disorder, recent gastric bleeding or hemorrhagic stroke in past 3 months
Poor response or serious adverse event with sertraline in the past.
Comparison group
Inclusion Criteria:
- English-speaking
Exclusion Criteria:
Lifetime diagnosis of depression or dementia
Currently on antidepressant medication or mood stabilizer
Poor baseline mobility or baseline severe gait disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea Iaboni, MD DPhil
Organizational Affiliation
University Health Network and University of Toronto
Official's Role
Principal Investigator
Facility Information:
Facility Name
Toronto Rehabilitation Institute, University Health Network
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G2A2
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults
We'll reach out to this number within 24 hrs